From Racheal Crowther’s examination into the ethics of care to SAGG Napoli’s immersive archery installation dissecting ...

Long Sleeve Hoodie Primark on sale, Peque ito Haul de Primark de la sudadera de Chip y Chop on sale, The sweetest daisy duck collection at Primark disneyclothes on sale, Anabel Pantoja triunfa con la ...

Texas Attorney General Ken Paxton has launched an investigation into DeepSeek, the upstart Chinese artificial intelligence ...

For the fourth time in five months, the Prescription Medicines Code of Practice Authority (PMCPA) has ruled that Moderna brought discredit on the pharma industry. Moderna received the latest ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market in record time and quickly generating blockbuster revenue from it.

The U.S. government has handed Moderna almost $600 million to accelerate its work on various bird flu vaccines as well as work on mRNA vaccines for other influenza strains with pandemic potential.

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare industry ...

Moderna has lowered 2025 revenue guidance after a tough 2024 coronavirus vaccination season. However, the company aims to launch 10 new products over the next few years -- and that could lead to ...

Massachusetts-based Moderna will likely be the first to manufacture a bird flu vaccine, backed by hundreds of millions in government funding. The biopharmaceutical giant is developing the vaccine ...

Erica Denhoff / Icon Sportswire via Getty Images Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu. The biotech ...

Moderna stock has been under pressure amid declining sales of its COVID-19 vaccine. The company projects optimism in its long-term outlook, believing that several pending product approvals can ...

Moderna's recent stumbles make the company an acquisition target. Merck desperately needs Moderna's mRNA-based Personal Cancer Vaccines ("PCVs") to extend KEYTRUDA's patent protection beyond 2028 ...